Abstract
Symptomatic brain metastases are found in about 40% of patients with small cell lung cancer. Cranial irradiation is the first line treatment for this form of metastatic disease. Frequently brain metastases recur after this treatment or develop after prophylactic cranial irradiation. For these patients no effective antitumour therapy is available. In this study the efficacy of high dose etoposide 1.5 g m-2 was evaluated. In 10 (43%) out of 23 evaluable patients a response was seen. Toxicity was severe with five aplasia-related deaths. For palliative purposes this regimen is too toxic in heavily pretreated patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Postmus, P., Haaxma-Reiche, H., Sleijfer, D. et al. High dose etoposide for brain metastases of small cell lung cancer. A phase II study. Br J Cancer 59, 254–256 (1989). https://doi.org/10.1038/bjc.1989.52
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.52
This article is cited by
-
Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?
Journal of Radiation Oncology (2017)
-
Treatment options for small cell lung cancer – do we have more choice?
British Journal of Cancer (2010)
-
Successful treatment of cranial metastases of extrapulmonary small cell carcinoma with chemotherapy alone
Medical Oncology (1998)
-
Penetration of etoposide into human malignant brain tumors after intravenous and oral administration
Cancer Chemotherapy and Pharmacology (1992)